Keros Therapeutics (KROS) Operating Leases (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Operating Leases came in at $14.5 million in Q4 2025, down 14.26% YoY from $16.9 million in Q4 2024, and down 4.21% on a QoQ basis from $15.1 million in Q3 2025.
Keros Therapeutics (KROS) Operating Leases (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Operating Leases data on file, last reported at $14.5 million in Q4 2025.
- Quarterly Operating Leases fell 14.26% year-over-year to $14.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.5 million (down 14.26% YoY) and the FY2025 annual result came in at $14.5 million, down 14.26% from the prior year.
- Operating Leases retreated to $14.5 million in Q4 2025, from $15.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $17.4 million in Q3 2024 to a low of $231000.0 in Q4 2021.
- A 5-year average of $10.5 million and a median of $13.4 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2021 — Operating Leases plunged 65.03% — and 2022, when it surged 5484.42%.
- Tracing KROS's Operating Leases over 5 years: stood at $231000.0 in 2021, then surged by 5484.42% to $12.9 million in 2022, then grew by 4.18% to $13.4 million in 2023, then advanced by 25.63% to $16.9 million in 2024, then declined by 14.26% to $14.5 million in 2025.
- The last three Operating Leases figures came in at $14.5 million (Q4 2025), $15.1 million (Q3 2025), and $15.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - |
| 10 | Keros Therapeutics | 216.02 Mn | -41.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.13 Mn |
| Dec 31, 2025 | 14.48 Mn |
| Sep 30, 2025 | 15.11 Mn |
| Jun 30, 2025 | 15.72 Mn |
| Mar 31, 2025 | 16.31 Mn |
| Dec 31, 2024 | 16.88 Mn |
| Sep 30, 2024 | 17.43 Mn |
| Jun 30, 2024 | 12.86 Mn |
| Mar 31, 2024 | 13.15 Mn |
| Dec 31, 2023 | 13.44 Mn |
| Sep 30, 2023 | 13.70 Mn |
| Jun 30, 2023 | 13.95 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | 12.90 Mn |
| Dec 31, 2021 | 231,000.00 |
| Sep 30, 2021 | 700,000.00 |
| Jun 30, 2021 | 242,000.00 |
| Mar 31, 2021 | 361,000.00 |
| Dec 31, 2020 | 476,000.00 |
| Sep 30, 2020 | 586,000.00 |